{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:58Z","timestamp":1786987798931,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ebiom.2024.105151","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T18:00:47Z","timestamp":1715277647000},"page":"105151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ex\u00a0vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-5291","authenticated-orcid":false,"given":"M. Ali","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Blazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse S.","family":"Justement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke D.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maegan R.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Sneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice K.","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Wook","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9903","key":"10.1016\/j.ebiom.2024.105151_bib1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105151_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMct1215532","article-title":"Single-pill combination regimens for treatment of HIV-1 infection","volume":"371","author":"Gandhi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105151_bib3","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.ebiom.2024.105151_bib4","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","article-title":"HIV drug resistance in low-income and middle-income countries","volume":"5","author":"Hamers","year":"2018","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105151_bib5","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/QAI.0000000000001534","article-title":"Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis","volume":"76","author":"Markowitz","year":"2017","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ebiom.2024.105151_bib6","series-title":"HIV drug resistance report","year":"2021"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105151_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.antiviral.2011.09.010","article-title":"The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment","volume":"92","author":"Fessel","year":"2011","journal-title":"Antivir Res"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105151_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","article-title":"Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection","volume":"14","author":"Volpe","year":"2015","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105151_bib9","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas","year":"2020","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105151_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105151_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0000000000001602","article-title":"Viral drug resistance through 48 Weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir","volume":"77","author":"Lataillade","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.ebiom.2024.105151_bib12","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ebiom.2024.105151_bib13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105151_bib14","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"7913","key":"10.1016\/j.ebiom.2024.105151_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"issue":"7913","key":"10.1016\/j.ebiom.2024.105151_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ebiom.2024.105151_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","article-title":"Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption","volume":"380","author":"Wang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105151_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat Med"},{"issue":"7742","key":"10.1016\/j.ebiom.2024.105151_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A\u00a0quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ebiom.2024.105151_bib20","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105151_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41591-021-01503-6","article-title":"Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy","volume":"27","author":"Blazkova","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105151_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/ciz590","article-title":"Eight-day inpatient directly observed therapy for antiretroviral therapy (ART) failure: a tool for preventing unnecessary ART changes and optimizing adherence support","volume":"70","author":"Winchester","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105151_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"Tang","year":"2012","journal-title":"Intervirology"},{"key":"10.1016\/j.ebiom.2024.105151_bib24","article-title":"Immunologic and virologic parameters associated with HIV DNA reservoir size in people living with HIV receiving antiretroviral therapy","author":"Blazkova","year":"2023","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105151_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132997","article-title":"Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy","volume":"5","author":"Peluso","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105151_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120326119","article-title":"Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy","volume":"119","author":"White","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105151_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117630119","article-title":"Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing","volume":"119","author":"Cho","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2024.105151_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J\u00a0Immunol Methods"},{"issue":"18","key":"10.1016\/j.ebiom.2024.105151_bib29","doi-asserted-by":"crossref","first-page":"10367","DOI":"10.1073\/pnas.96.18.10367","article-title":"Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex","volume":"96","author":"Wang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T09:20:15Z","timestamp":1718529615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"alternative-id":["S2352396424001865"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105151","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex\u00a0vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105151"}}